Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Placental Pathology as a Tool to Identify Women for Postpartum Cardiovascular Risk Screening Following Preeclampsia: A Preliminary Investigation

Version 1 : Received: 22 January 2022 / Approved: 24 January 2022 / Online: 24 January 2022 (14:27:20 CET)

A peer-reviewed article of this Preprint also exists.

Benton, S.J.; Mery, E.E.; Grynspan, D.; Gaudet, L.M.; Smith, G.N.; Bainbridge, S.A. Placental Pathology as a Tool to Identify Women for Postpartum Cardiovascular Risk Screening following Preeclampsia: A Preliminary Investigation. J. Clin. Med. 2022, 11, 1576. Benton, S.J.; Mery, E.E.; Grynspan, D.; Gaudet, L.M.; Smith, G.N.; Bainbridge, S.A. Placental Pathology as a Tool to Identify Women for Postpartum Cardiovascular Risk Screening following Preeclampsia: A Preliminary Investigation. J. Clin. Med. 2022, 11, 1576.

Abstract

Preeclampsia (PE) is associated with an increased risk of cardiovascular disease (CVD) in later life. Postpartum cardiovascular risk screening could identify patients who would benefit most from lifestyle interventions. However, there are no readily available methods to identify these high-risk women. We propose that placental lesions may be useful in this regard. Here, we sought to determine the association between placental lesions and lifetime CVD risk. Placentas from 85 PE women were evaluated for histopathological lesions. At 6 months postpartum, a lifetime cardiovascular risk score was calculated. Placental lesions were compared between CVD risk groups and the association was assessed using odds ratios. Multivariable logistic regression was used to develop prediction models for CVD risk with placental pathology. Placentas from high-risk women had more severe lesions of maternal vascular malperfusion (MVM) and resulted in a 3-fold increased risk of screening high-risk for CVD (OR 3.10[1.20-7.92]) compared to women without these lesions. MVM lesion severity was moderately predictive of high-risk screening (AUC 0.63[0.51,0.75]; sensitivity 71.8%[54.6,84.4]; specificity 54.7%[41.5,67.3]. When clinical parameters were added, the model’s predictive performance improved (AUC 0.73[0.62,0.84]; sensitivity 78.4%[65.4,87.5]; specificity 51.6%[34.8,68.0]. The results suggest that placenta pathology may provide a unique modality to identify women for cardiovascular screening.

Keywords

preeclampsia; placenta; histopathology; cardiovascular disease; cardiovascular risk; postpartum

Subject

Medicine and Pharmacology, Obstetrics and Gynaecology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.